October 4, 2022

The first steps towards aging medication

Everyone wants a softer skin, thicker hair, and wrinkles until aging. In essence, everyone wants to preserve the virtues of youth.

However, we have not been able to find the remedy for hair loss, let alone find a remedy for that inevitable fall in the health, beauty, and energy we all have to face at some point. We can collect all creams for anti-aging, vitamin supplements, and botoxes, but these are temporary solutions; what we all expect is the magic elixir, which will be some form of youth elixir.

According to a new study, scientists may have finally made some steps toward a potential anti-aging drug (and no, it is not exercise, though exercises certainly have a positive impact on youth retention). Medication, which is a version of the drug known as rapamycin, resulted in reinforcing the immune system in the elderly in relation to influenza vaccine responses by 20 percent. The study was published in Science Translational Medicine.

Rapamycin belongs to a group of drugs called mTOR inhibitors, which have been shown in previous functional studies as an anti-aging agent. While people get older, mTOR genetic pathways seem to have a negative effect, though they support healthy growth of children (this applies to all mammals). Therefore, the use of rapamycin to prevent the genetic pathway of mTOR, in theory, may delay aging. In a 2013 study, for example, researchers discovered that rapamycin functioned in increasing the “maximum lifespan” in mice.

However, this is the first time scientists are studying the effect of rapamycin on humans. While more research is needed to better assess whether rapamycin can extend human life expectancy as it does in mice, the study shows that it stimulates the immune system of the elderly, particularly against the flu, which may be particularly dangerous for the elderly. For study, elderly participants who had received the experimental dose of rapamycin had 20 percent more antibody response to flu vaccine than people who did not receive rapamycin. In addition, rapamycin lowered the amount of white blood cells that are typically associated with aging and the immune depletion.

Scientists have worked on creating an elixir for anti-aging for a while already. Last year, a study conducted by Harvard University and the University of New South Wales examined another path to the same conclusion by injecting a chemical called nicotinamide adenine dinucleotide (NAD) into mice, which turned the process aging. But developing a drug using this complex will take several more years.

“The aging factor is a major risk factor for the killers we are afraid of,” said dr. Nir Barzilai, director of the Albert Einstein College of Medicine at New York Institute of Elderly Research and author of the latest study, HealthDay.

“If aging is the greatest risk, the way to extend people’s lives and improve their health is to delay aging.” By calling the study a baby step, Barzillai said, “He sets the basics for using this drug to target aging, to improve everything about aging. That will be for us a turning point in the quest, and we are very excited about it “.

Leave a Reply

Your email address will not be published.